Swiss healthcare company Roche has secured the CE Mark for its new SARS-CoV-2 Rapid Antigen Test Nasal, a test kit for Covid-19.
Roche plans to make the test available in countries that accept the CE mark by the middle of this month.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
When compared to its previous product Roche SARS-CoV-2 Rapid Antigen Test, the new SARS-CoV-2 Rapid Antigen Test Nasal will collect the sample from the front area of the nose instead of the nasopharynx, making it a simple and fast testing method.
As a less invasive test, it can also be used by patients self-collecting the nasal sample under the supervision of a healthcare professional. It can further reduce the risk of virus exposure for healthcare professionals.
The SARS-CoV-2 Rapid Antigen Test Nasal is a rapid chromatographic immunoassay to detect the nucleocapsid protein from the SARS-CoV-2 virus in the human nasal specimens.
Roche’s clinical studies claim that the test had a relative sensitivity of 90.6% and a specificity of 98.6% for professionally collected samples, and in self-collected samples, the sensitivity was recorded at 84.4 % with a specificity of 99.2%.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataRoche Diagnostics CEO Thomas Schinecker said: “Rapid testing continues to play an important role in the fight against Covid-19, especially in places when laboratory testing is not available and quick results are needed, such as nursing homes, healthcare facilities, and schools.
“The SARS-CoV-2 Rapid Antigen Test Nasal provides patients with a more comfortable testing experience.”
The new test is being launched by Roche, in partnership with SD Biosensor, a company with which it had previously launched a SARS-CoV-2 Rapid Antibody Test in July and a SARS-CoV-2 Rapid Antigen Test in September.
Meanwhile, Ellume, a digital diagnostics firm, had signed a $231.8m agreement with the US Department of Defense (DoD), in coordination with the Department of Health and Human Services (HHS), to speed up the production of its Covid-19 home tests.
Authorised by the US Food and Drug Administration (FDA), Ellume COVID-19 Home Test is a rapid self-test and can be used in both asymptomatic and symptomatic cases.
The agreement includes funding to support Ellume in establishing a manufacturing facility in the US and to deliver 8.5 million of the tests to be distributed across the country.
